U.S. Personal Products Stock News

Stock performance snapshot and business overview Rhythm Pharmaceuticals (RYTM) has seen mixed trading recently, with the stock up 3.4% over the past day but down over the past week, month and past 3 months. Year to date, the share price is also lower. Over a longer horizon, total return over the past year is positive, and over the past 3 and 5 years the stock shows very large cumulative gains. The current share price is US$87.61, giving the company a market value of about US$5.8b. Rhythm...

Recent performance snapshot S&P Global (SPGI) stock has fallen about 18% year to date, with total return over the past year also down roughly 18%. This puts recent performance in contrast with its longer term multi year record. See our latest analysis for S&P Global. The recent 1 day share price return of 1.9% to US$420.12 comes after a steady loss of momentum, with the 90 day share price return down 7.1% and the 1 year total shareholder return down 17.9%, even though the 5 year total...

Unity Software (U) is back in focus after recent analyst upgrades, including commentary on progress in its Grow advertising business and higher earnings estimates that together underline shifting expectations around the company’s execution and monetization. See our latest analysis for Unity Software. Unity’s recent analyst upgrades and improving sentiment around its Grow ad business sit alongside a mixed price story, with the stock’s 90 day share price return of 51.28% contrasting with a year...

Kodiak Sciences (NasdaqGM:KOD) reported positive phase III results for its drug candidate Zenkuda in diabetic retinopathy. The company is accelerating regulatory submissions following the data readout, aiming to move the program toward potential approval. Kodiak Sciences is drawing fresh attention after this clinical update, with the stock at $34.16 and up strongly year to date, including a very large gain over the past 1 year. At the same time, shares are down 5.4% over the past week and...

In recent days, Oshkosh Defense, a business of Oshkosh Corporation, announced multiple past contract wins with the U.S. Marine Corps, including US$92,000,000 in ROGUE-Fires Block 2 production orders for semi-autonomous ground vehicles and US$142,000,000 in new Family of Medium Tactical Vehicles A2 orders from U.S. and international customers. These awards highlight Oshkosh’s growing role in autonomous ground combat systems and modern tactical fleets, reinforcing its exposure to large,...

If you are wondering whether Kenvue's current share price offers value, or if you are better off waiting on the sidelines, this article breaks down what the market is pricing in and how that compares with several valuation checks. The stock recently closed at US$16.88 and has fallen 4.3% over the last week, 2.8% over the last month, and 2.5% year to date. The return over the past year is down 18.4% and down 24.1% over three years. Recent news flow around Kenvue has focused on its position as...

Stock performance snapshot and recent context Vertex Pharmaceuticals (VRTX) has drawn investor attention after recent trading left the stock with a 1 day gain of about 3.1%, while returns over the past 3 months show a decline of roughly 3.3%. See our latest analysis for Vertex Pharmaceuticals. That move comes on top of a 4.1% 1 month share price return and a 1 year total shareholder return that is roughly flat, while the 5 year total shareholder return above 100% points to stronger long term...

Some Axon Enterprise, Inc. ( NASDAQ:AXON ) shareholders may be a little concerned to see that the COO & CFO, Brittany...

How Berkshire Hathaway stock has been trading Berkshire Hathaway (BRK.B) has seen relatively muted short term moves, with the stock roughly flat over the past week and posting a gain of about 3% over the past month. Over longer periods, the picture is mixed. The stock has declined about 4% in the past 3 months and about 2% over the past year, while total return over 3 and 5 years remains clearly positive. See our latest analysis for Berkshire Hathaway. At a share price of US$478.63, Berkshire...

Elastic (ESTC) is back in focus after its latest earnings, where the company moved from a loss to profitability and reported higher revenue, supported by AI powered search, observability, security and multi year contracts. See our latest analysis for Elastic. That earnings beat and guidance have helped the stock regain some ground, with a 30 day share price return of 29.8% and a 90 day share price return of 21.1%, although the 1 year total shareholder return is still down 24.6% and longer...

Recently, BlackRock capped investor withdrawals from its approximately US$26.00 billion HPS Corporate Lending Fund at 5% of shares, below requested levels, to manage liquidity against the longer-term nature of its private credit loans and ease pressure on the fund’s structure. This move has intensified attention on liquidity management and risk in private credit vehicles, raising questions about how BlackRock balances investor access with the realities of less liquid, higher-yielding assets...

If you are wondering whether Allison Transmission Holdings at around US$118 a share still offers value, the starting point is understanding what the current price is really baking in. The stock has been volatile recently, with a 4.3% gain over the last week, a 7.1% decline over the last month, and returns of 19.6% year to date and 16.8% over the past year that may catch your eye. These moves sit against a backdrop of ongoing interest in capital goods companies and how investors are pricing...

Q1 miss puts SouthState Bank (SSB) under closer investor scrutiny SouthState Bank (SSB) recently reported a softer quarter, missing analyst expectations for revenue and net interest income, and the stock has slipped 3.4% since the release. The weaker print arrives as regional banks contend with fintech competition, deposit outflows, credit quality concerns, and higher regulatory costs. This keeps investors focused on how efficiently each bank manages earnings and balance sheet risk. See our...

SunPower’s equity and debt moves SunPower (SPWR) has moved to close a US$40.7 million shelf registration and is now seeking to pay upcoming interest on its 2029 convertible notes in stock plus bonus shares instead of cash. This combination of equity capacity, proposed share-based interest payments, and a recent incremental investment from Fortis Capital is intended to give the company more room to manage liquidity through Q3 2026. See our latest analysis for SunPower. Recent announcements...

If you are wondering whether Datadog's share price still makes sense after a strong run, the key question is how that price compares with what the business might be worth. The stock last closed at US$243.60, with returns of 8.2% over 7 days, 67.2% over 30 days, 82.1% year to date, 100.1% over 1 year, 153.7% over 3 years and 157.8% over 5 years. That performance naturally raises questions about how much future performance is already reflected in the price. Recent attention on Datadog has...

Charles River Laboratories International recently presented at the William Blair Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York, outlining its current strategic focus, business developments, and recent trends via live and archived webcasts for investors. These appearances highlighted CEO Birgit Girshick’s new “Pathway to Purpose” framework and ongoing portfolio reshaping, including divestitures of CDMO, Cell Solutions, and selected European...

Earlier this week, Raymond James upgraded Atlas Energy Solutions from Market Perform to Outperform after the company reported first-quarter 2026 results and detailed expanded distributed power growth plans, including a global framework agreement with Caterpillar for 1.4 GW of power capacity and a US$450 million convertible senior notes offering to fund expansion toward 2 GW. The upgrade underscores how Atlas is increasingly being viewed not just as a Permian proppant and logistics provider,...

In recent days, Conagra Brands reported quarterly results with slightly lower year-over-year revenue that still exceeded analyst expectations, alongside mixed profit guidance affected by commodity cost pressures. At the same time, several analysts warned that persistent inflation and a high payout ratio could put Conagra’s dividend policy under scrutiny, even as insiders accepted additional equity awards. We’ll now examine how concerns about inflation-driven cost pressures and potential...

Why Pinterest’s $4 Billion AWS Deal Matters for the Stock Pinterest (PINS) has committed US$4b to Amazon Web Services through 2031, its largest infrastructure agreement to date, to support AI model development, faster search and shopping, and global platform modernization. See our latest analysis for Pinterest. The AWS commitment lands after a volatile stretch for Pinterest, with the share price up 4.5% over the past week and 7.9% over 90 days, yet down 18.7% year to date and a 36.1% total...

Clinical data catalyst and recent stock move Enliven Therapeutics (ELVN) is back in focus after the company highlighted upcoming Phase 1 ENABLE trial data for ELVN-001 in chronic myeloid leukemia, set to be presented at the European Hematology Association Congress. The company plans a June 11 webcast to walk through the updated results. This, together with recent positive analyst commentary, has drawn fresh attention to a stock that is up 66.1% over the past year. See our latest analysis for...

Recently, Credicorp reported a strong first quarter with a 21.1% return on equity and declared a record dividend of 50 soles per share, citing robust solvency and confidence in its business trajectory. The company’s dividend yield now stands well above industry and S&P 500 averages, underpinned by several years of dividend growth and earnings that analysts view as supportive of ongoing payouts. Next, we’ll examine how Credicorp’s record dividend and solid first-quarter profitability...

Recent price moves and renewed interest in Qualys Recent gains in Qualys (QLYS) have drawn fresh attention, as the stock rose 11.1% over the past week and 21.0% over the past month, even as longer term returns remain weaker. This move comes as some valuation models suggest the shares trade below certain fair value estimates. This has prompted some investors to reassess the cybersecurity and cloud-based security provider's positioning within their portfolios. See our latest analysis for...

In late May and early June 2026, Agios Pharmaceuticals halted development of tebapivat in lower-risk myelodysplastic syndromes, gained European Commission approval for PYRUKYND (mitapivat) in thalassemia across all EU member states, and licensed exclusive global rights to cevidoplenib, an oral SYK inhibitor, from Oscotec for immune thrombocytopenia and other indications. Together, these updates reshape Agios’s mix of commercial products and pipeline assets, trading one unpromising program...

If you are wondering whether Microchip Technology at around US$96.30 is still offering value or if the easier gains are behind it, this breakdown will help you weigh what the current price really implies. The stock is roughly flat over the past week with a 0.3% gain, a little softer over the last month with a 2.2% decline, yet stands out with returns of 48.1% year to date and 53.7% over the past year. Recent coverage has focused on Microchip Technology's role within the broader semiconductor...